0001209191-22-036567.txt : 20220614
0001209191-22-036567.hdr.sgml : 20220614
20220614074830
ACCESSION NUMBER: 0001209191-22-036567
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220610
FILED AS OF DATE: 20220614
DATE AS OF CHANGE: 20220614
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Edwards Martin
CENTRAL INDEX KEY: 0001640073
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39397
FILM NUMBER: 221013453
MAIL ADDRESS:
STREET 1: 15 NEW ENGLAND EXECUTIVE PARK
CITY: BURLINGTON
STATE: MA
ZIP: 01803
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Inozyme Pharma, Inc.
CENTRAL INDEX KEY: 0001693011
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 475129768
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 321 SUMMER STREET
STREET 2: SUITE 400
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 857-330-4340
MAIL ADDRESS:
STREET 1: 321 SUMMER STREET
STREET 2: SUITE 400
CITY: BOSTON
STATE: MA
ZIP: 02210
FORMER COMPANY:
FORMER CONFORMED NAME: Inozyme Pharma, LLC
DATE OF NAME CHANGE: 20161222
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-06-10
0
0001693011
Inozyme Pharma, Inc.
INZY
0001640073
Edwards Martin
C/O INOZYME PHARMA, INC.
321 SUMMER STREET SUITE 400
BOSTON
MA
02210
1
0
0
0
Stock Option (right to buy)
4.38
2022-06-10
4
A
0
9367
0.00
A
2032-06-09
Common Stock
9367
9367
D
The option was granted on June 10, 2022. The shares underlying the option are scheduled to vest as to 100% of the shares on June 10, 2023, or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date.
/s/ Axel Bolte, as attorney-in-fact for Martin Edwards
2022-06-14